ZA962592B - Transdermally administrable medicament with ace inhibitors. - Google Patents

Transdermally administrable medicament with ace inhibitors.

Info

Publication number
ZA962592B
ZA962592B ZA9602592A ZA962592A ZA962592B ZA 962592 B ZA962592 B ZA 962592B ZA 9602592 A ZA9602592 A ZA 9602592A ZA 962592 A ZA962592 A ZA 962592A ZA 962592 B ZA962592 B ZA 962592B
Authority
ZA
South Africa
Prior art keywords
ace inhibitors
transdermally administrable
administrable medicament
medicament
transdermally
Prior art date
Application number
ZA9602592A
Other languages
English (en)
Inventor
Wilfried Fisher
Karin Klokkers
Original Assignee
Hexal Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexal Ag filed Critical Hexal Ag
Publication of ZA962592B publication Critical patent/ZA962592B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA9602592A 1995-03-31 1996-04-01 Transdermally administrable medicament with ace inhibitors. ZA962592B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19512181A DE19512181C2 (de) 1995-03-31 1995-03-31 Transdermales System mit Ramipril und/oder Trandolapril als ACE-Hemmer

Publications (1)

Publication Number Publication Date
ZA962592B true ZA962592B (en) 1997-10-01

Family

ID=7758491

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9602592A ZA962592B (en) 1995-03-31 1996-04-01 Transdermally administrable medicament with ace inhibitors.

Country Status (19)

Country Link
US (1) US6303141B1 (pt)
EP (1) EP0817622B1 (pt)
JP (1) JP3924008B2 (pt)
AT (1) ATE209482T1 (pt)
AU (1) AU700418B2 (pt)
BR (1) BR9607872A (pt)
CA (1) CA2216278A1 (pt)
CZ (1) CZ287373B6 (pt)
DE (2) DE19512181C2 (pt)
DK (1) DK0817622T3 (pt)
ES (1) ES2167558T3 (pt)
HU (1) HUP9801989A3 (pt)
NO (1) NO974508L (pt)
NZ (1) NZ306429A (pt)
PL (1) PL322576A1 (pt)
PT (1) PT817622E (pt)
SK (1) SK125897A3 (pt)
WO (1) WO1996029999A1 (pt)
ZA (1) ZA962592B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
DE19820151A1 (de) * 1998-05-06 1999-11-11 Hexal Ag Transdermales therapeutisches System zur Anwendung von Candesartan
DE69825495T2 (de) 1998-12-23 2005-07-28 Idea Ag Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo
SI1031347T1 (en) 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
PT1031346E (pt) 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
DE10033855A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Matrixkontrolliertes transdermales System mit Sulfonsäuresalz eines ACE-Hemmers
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
KR100988542B1 (ko) * 2001-06-18 2010-10-20 노벤 파머수티컬즈, 인코퍼레이티드 경피 시스템에서의 강화된 약물 전달
US6805878B2 (en) * 2001-09-13 2004-10-19 Noven Pharmaceuticals, Inc. Transdermal administration of ACE inhibitors
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
CA2584475A1 (en) * 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions
EP1704876A1 (en) * 2005-03-24 2006-09-27 NOLabs AB Cosmetic treatment, device for performing said treatment and manufacturing method thereof
EP1871433B1 (en) 2005-03-24 2009-04-22 NOLabs AB Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor
JP5058531B2 (ja) 2005-09-09 2012-10-24 日東電工株式会社 ビソプロロール含有貼付製剤
DE102005058166A1 (de) 2005-12-05 2007-06-06 Hexal Ag Matrixkontrolliertes transdermales System mit Amin-Salzen der ACE-Hemmer-Dicarbonsäuren
JP4945228B2 (ja) * 2005-12-13 2012-06-06 日東電工株式会社 ビソプロロール含有貼付製剤
JP5015562B2 (ja) * 2005-12-13 2012-08-29 日東電工株式会社 貼付製剤
US7943655B2 (en) * 2006-04-05 2011-05-17 Universitat Zurich Polymorphic and pseudopolymorphic forms of trandolaprilat, pharmaceutical compositions and methods for production and use
CN103784425B (zh) 2007-03-08 2016-08-17 日东电工株式会社 比索洛尔的经皮给药装置
ES2804263T3 (es) 2011-07-05 2021-02-05 Novan Inc Composiciones tópicas
US9855211B2 (en) 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
US11813284B2 (en) 2013-08-08 2023-11-14 Novan, Inc. Topical compositions and methods of using the same
EP3177262A4 (en) 2014-08-08 2018-04-18 Novan Inc. Topical emulsions
US10912743B2 (en) 2016-03-02 2021-02-09 Novan, Inc. Compositions for treating inflammation and methods of treating the same
US11166980B2 (en) 2016-04-13 2021-11-09 Novan, Inc. Compositions, systems, kits, and methods for treating an infection

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256687A (en) * 1985-09-09 1993-10-26 Hoechst Aktiengesellschaft Pharmaceutical composition for the treatment of high blood pressure
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4898732A (en) * 1988-05-04 1990-02-06 The Clinipad Corporation Inhibiting of tumor growth with an antagonist of the renin-angioten-sin system
US5269875A (en) 1989-10-05 1993-12-14 Shin-Etsu Handotai Company, Limited Method of adjusting concentration of oxygen in silicon single crystal and apparatus for use in the method
JPH0774116B2 (ja) * 1989-10-05 1995-08-09 信越半導体株式会社 Ｓｉ単結晶中の酸素濃度調整方法およびその装置
US5073539A (en) * 1990-01-22 1991-12-17 Ciba-Geigy Corporation Transdermal administration of zwitterionic drugs
JP2849937B2 (ja) 1990-04-18 1999-01-27 日東電工株式会社 医療用貼付剤
FR2664815B1 (fr) 1990-07-23 1994-11-04 Adir Systeme matriciel autoadhesif pour la liberation prolongee du piribedil par voie transcutanee.
US5464387A (en) * 1991-07-24 1995-11-07 Alza Corporation Transdermal delivery device
WO1993023019A1 (en) * 1992-05-11 1993-11-25 Sri International Transdermal drug delivery systems and related compositions and methods of use

Also Published As

Publication number Publication date
AU700418B2 (en) 1999-01-07
CZ302897A3 (cs) 1998-02-18
MX9707507A (es) 1997-11-29
WO1996029999A1 (de) 1996-10-03
BR9607872A (pt) 1999-11-30
HUP9801989A3 (en) 2000-06-28
DE59608323D1 (de) 2002-01-10
CA2216278A1 (en) 1996-10-03
US6303141B1 (en) 2001-10-16
DE19512181A1 (de) 1996-10-02
NZ306429A (en) 2000-07-28
ES2167558T3 (es) 2002-05-16
HUP9801989A2 (hu) 1999-02-01
EP0817622A1 (de) 1998-01-14
ATE209482T1 (de) 2001-12-15
NO974508L (no) 1997-10-27
DE19512181C2 (de) 2003-11-06
EP0817622B1 (de) 2001-11-28
NO974508D0 (no) 1997-09-29
PT817622E (pt) 2002-05-31
PL322576A1 (en) 1998-02-02
SK125897A3 (en) 1998-02-04
JP3924008B2 (ja) 2007-06-06
DK0817622T3 (da) 2002-03-25
CZ287373B6 (en) 2000-11-15
JPH11502827A (ja) 1999-03-09
AU5498296A (en) 1996-10-16

Similar Documents

Publication Publication Date Title
ZA962592B (en) Transdermally administrable medicament with ace inhibitors.
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
AU5533094A (en) Enzyme inhibitors
ES2144019T3 (es) Composicion farmaceutica que contiene inhibidores de glucosidasa y/o de amilasa, y un inhibidor de lipasa.
MY111370A (en) Dual action inhibitors
PL324330A1 (en) Do- and trivalent low-molecule selectin inhibitors
ZA973397B (en) Inhibitors of IMPDH enzyme.
ZA9610729B (en) Transdermal device for the delivery of flurbiprofen.
ATE230393T1 (de) Ace-inhibitoren stickstoffsalze
TW327172B (en) Novel mercaptoacetylamide bicyclic lactam derivatives
TW225534B (pt)
AU2895392A (en) Transdermal therapeutic systems containing crystallization inhibitors
AU9021498A (en) Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
HUP9802764A3 (en) Guanidino protease inhibitors
NZ308516A (en) Transdermal therapeutic system (tts) for administering testosterone
EP0858262A4 (en) THROMBIN INHIBITORS
CA2055948A1 (en) Use of a combination of angiotensin-converting enzyme inhibitor and calcium antagonist for the treatment of proteinuria
FI962369L (fi) Farmaseuttinen formulointi myrkytyksen ehkäisemiseksi tai esihoidoksi organofosforisilla koliiniesteraasi-inhibiittoreilla
ZA934970B (en) Enzyme inhibitors
AU637861B2 (en) Improved system for the transdermal application of pharmacologically active compounds at controlled ph
SI0817622T1 (en) Medicament with angiotensin converting enzyme (ace) inhibitors suitable for transdermal application
ZA939480B (en) Enzyme inhibitor
GB9324803D0 (en) Enzyme inhibitors
GB9324981D0 (en) Enzyme inhibitors
MX9709511A (es) Inhibidores de selectina de moleculas pequeñas divalentes y trivalentes.